RecruitingPhase 2Phase 3NCT05828953

Anlotinib Capsules in the Treatment for IPF/PF-ILDs

A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Anlotinib Capsules for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)/Progressive Fibrosis-interstitial Lung Disease (PF-ILDs)

Sponsor

First Affiliated Hospital of Wenzhou Medical University

Enrollment

30 participants

Start Date

Sep 28, 2021

Study Type

INTERVENTIONAL

Conditions

Interstitial Lung Diseases

Summary

The use of Anlotinib hydrochloride capsules for the treatment of IPF/PF-ILDs, with FVC as the primary efficacy endpoint to evaluate its effectivenes

Eligibility

Min Age: 40 YearsMax Age: 85 Years

Inclusion Criteria10

The participants voluntarily joined the study and signed an informed consent form. They showed good compliance throughout the study.
The study includes individuals aged 40-85 years old, of any gender, with an expected lifespan of over 1 year.
Subjects who meet either of the following two criteria: a. HRCT results confirming IPF diagnosis within the past 5 years and HRCT results within the past 12 months showing a range of parenchymal fibrotic changes between ≥10% and \<50%, with less than 25% honeycombing change in the lung, and no other facilitating factors (e.g. asbestos exposure, allergic pneumonia, systemic sclerosis, rheumatoid arthritis) as detailed in Annex 1A. b. PF-ILDs: Patients with characteristics of fibrotic lung disease (see Annex 1B), and at least one of the following diagnostic criteria is met: i. Relative decline in FVC% predicted by ≥10% within 6 months; ii. Relative decline in FVC% predicted by ≥5-10% with worsening respiratory symptoms, or an increase in the degree of fibrosis on chest HRCT; ii. Worsening respiratory symptoms combined with an increase in the degree of fibrosis on chest HRCT;
Carbon monoxide diffusion capacity (DLco) (corrected for hemoglobin) between 30% and 80% of predicted value;
Force vital capacity (FVC) ≥ 45% predicted;
The 6MWT distance is ≥ 150 meters
Arterial partial pressure of oxygen (PaO2) ≥ 60 mmHg (measured at sea level atmospheric pressure, at rest, and breathing room air)
"Major organ functions are good, and meet the following criteria: a. Standard blood routine examination (not corrected by blood transfusion or hematopoietic growth factor drugs in the past 7 days): hemoglobin (HGB) ≥ 90 g/L; absolute neutrophil count (NEUT) ≥ 1.5 × 10\^9/L; platelet count (PLT) ≥ 90 × 10\^9/L; b. Biochemical examination should meet the following criteria: total bilirubin (TBL) ≤ 1.5 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; serum creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance rate (Ccr) ≥ 60 ml/min; c. Coagulation function or thyroid function examination should meet the following criteria: prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (NR) ≤ 1.5 × ULN (not receiving anticoagulation therapy) or stable use of anticoagulants in the 2 weeks before enrollment; d. Thyroid-stimulating hormone (TSH) ≤ ULN after standard treatment; if abnormal, T3 and T4 levels should be investigated and can be enrolled if T3 and T4 levels are normal.
e. Echocardiography evaluation: Left ventricular ejection fraction (LVEF) ≥50%
Female participants of childbearing potential must agree to use contraception (such as intrauterine device, contraceptive pill, or condom) during the study and for 6 months after the end of the study; must have a negative serum pregnancy test within 7 days before study entry and must not be lactating. Male participants must agree to use contraception during the study and for 6 months after the end of the study.

Exclusion Criteria20

Patients with acute exacerbation of PF/PF-ILDs.;
Multiple factors that affect oral medication (such as dysphagia, chronic diarrhea, and intestinal obstruction)
Received major surgical treatment, incisional biopsy, or significant traumatic injury within 28 days prior to the start of the study treatment.
Long-standing non-healing wound or fracture.
Patients who have experienced thrombotic events, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, and cerebral infarction), deep vein thrombosis, and pulmonary embolism, within the past 6 months, or those with other bleeding tendencies.
Subjects with any severe or uncontrolled comorbidities or undergoing immunotherapy, such as:
Blood pressure remains uncontrolled even after antihypertensive therapy (systolic blood pressure ≥150mmHg or diastolic blood pressure ≥100mmHg); 2nd-degree myocardial ischemia or myocardial infarction, arrhythmia (including QTc ≥450ms (men), QTc ≥470ms (women)) or 2nd-degree congestive heart failure (New York Heart Association (NYHA) classification); pulmonary or systemic infections within 4 weeks before enrollment;
Severe pulmonary arterial hypertension (systolic pulmonary artery pressure (SPAP) ≥70mmHg);
Renal failure requiring hemodialysis or peritoneal dialysis;
History of immune deficiency diseases, including HIV-positive or other acquired or congenital immune deficiency diseases, or history of organ transplantation;
Known clinically significant liver disease history, including viral hepatitis, known carriers of hepatitis B virus (HBV) must exclude active HBV infection, i.e., HBV DNA positive (\>2500 copies/mL or \>500IU/mL, and greater than the upper limit of normal); known hepatitis C virus (HCV) infection and positive HCV RNA (\>1×103 copies/mL), or other decompensated liver diseases;
Fasting blood glucose (FBG) \>10mmol/L after administration of hypoglycemic drugs (poor blood glucose control patients);
Urine routine test indicates urine protein ≥+, and 24-hour urine protein quantitation is confirmed to be \>1.0g.
Received high-dose steroids (e.g. prednisone \>15mg/kg) within 1 month prior to randomization；
Use of immunosuppressants within 1 month prior to randomization after enrollment;
Long-term use (\>1 week) of drugs such as amiodarone that may cause pulmonary fibrosis prior to enrollment;
Received interferon, N-acetylcysteine (\>1800mg), or other anti-fibrotic drugs within 1 month prior to randomization
Received treatment with nintedanib or pirfenidone for less than 28 days before randomization.
Participation in other drug trials within 3 months prior to randomization
The researcher considers any ineligible candidates.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAnlotinib

Drug: Anlotinib The dose of nintedanib hydrochloride is 8mg per dose, taken orally once daily before breakfast. The drug is taken continuously for 2 weeks, followed by a 1-week break, until 24 weeks as the primary endpoint, to observe the long-term efficacy and safety of anlotinib in the treatment of IPF/PF-ILDs. After 24 weeks, the blinded administration was continued until 52 weeks. After 52 weeks, all subjects could enter the extension period if they wished. If a dose is missed and the next dose is due within 12 hours, it should not be made up.

DRUGPlacebo

Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until 24 weeks as the primary endpoint, to observe the long-term efficacy and safety of anlotinib in the treatment of IPF/PF-ILDs. After 24 weeks, the blinded administration was continued until 52 weeks. After 52 weeks, all subjects could enter the extension period if they wished. If a dose is missed and the next dose is due within 12 hours, it should not be made up.